NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 4 Years
Max Age: 75 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;



Recruitment Keyword(s)



Severe Aplastic Anemia;
Hypo-Plastic MDS;
Myelodysplastic Syndrome (MDS)

Investigational Drug(s)

Omidubicel (former CordIn)

Investigational Device(s)



Biological/Vaccine: Omidubicel (former CordIn)
Device: Miltenyi CliniMACS(R) CD34 Reagent System

Supporting Site

National Heart, Lung, and Blood Institute


Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant. Researchers are testing ways to make stem cell transplant safer and more effective.


To test if treating people with SAA or MDS with a co-infusion of blood stem cells from a family member and cord blood stem cells from an unrelated donor is safe and effective.


Recipients ages 4-60 with SAA or MDS

Donors ages 4-75


Recipients will be screened with:

-Blood, lung, and heart tests

-Bone marrow biopsy

-CT scan

Recipients will have an IV line placed into a vein in the neck. Starting 11 days before the transplant they will have several chemotherapy infusions and 1 30-minute radiation dose.

Recipients will get the donor cells through the IV line. They will stay in the hospital 3-4 weeks. After discharge, they will have visits:

-First 3-4 months: 1-2 times weekly

-Then every 6 months for 5 years<TAB>

Donors will be screened with:

-Physical exam

-Medical history

-Blood tests

Donors veins will be checked for suitability for stem cell collection. They may need an IV line to be placed in a thigh vein.

Donors will get filgrastim injections daily for 5-7 days. On the last day, they will have apheresis: Blood drawn from one arm or leg runs through a machine and into the other arm or leg. This may be repeated 2 days or 2-4 weeks later.

--Back to Top--



-Diagnosed with severe aplastic anemia with bone marrow cellularity <30% (excluding lymphocytes) associated with RBC or platelet transfusion dependence and/or neutropenia (absolute neutrophil count <=1000 cells/ uL or for patients receiving granulocyte transfusions, absolute neutrophil count <=1000 cells/ uL before beginning granulocyte transfusions).


History of severe aplastic anemia transformed to MDS that meet the following criteria: a) International Prognostic Scoring System (IPSS) risk category of INT-1 or greater, b) < 5% myeloblasts and < 30% of cellularity in the bone marrow on screening morphologic analysis.

-Intolerance of or failure to respond to standard immunosuppressive therapy.

Identification of either a) at least one alternative donor (i.e. HLA- haploidentical related donor (i.e. >=5/10 HLA match: HLA-A, B, C, DR, and DQ loci) or >=9/10 HLA matched unrelated donor) who is available to serve as a stem cell donor for a salvage allogeneic transplant in the event that the CordIn(TM) unit has been rejected or b) umbilical cord blood unit/s that can be used for a salvage cord blood transplant in the event that the CordIn(TM) unit has been rejected.

-Availability of at least one >=4/8 HLA matched (HLA-A, B, C, and DR loci) cord blood unit from the National Marrow Donor Program (NMDP).

The cord blood unit must contain a minimum TNC of at least 1.8 x 10^9 and at least 1.5x10^7/kg TNC and at least 8 x 10^6 CD34+ cells (all doses prior to thawing).

Exception: Cord units containing at least 8 x 10^6 CD34+ cells but less than 1.8 x 10^9 TNC may be eligible for use on this trial if

a) the pre-expansion CD34/kg recipient cell number is at least 1.5 x 10^5 /kg


b) approval for use of this cord unit for expansion is granted by Gamida Cell.

c) the final cell counts on the cultured and non-cultured fractions meet the IND specified minimal release criteria.

-The CBU will have undergone volume reduction (both plasma and red blood cell depletion) prior to cryopreservation. All CBUs should be procured from public banks that meet local applicable regulations.

-Ages 4-60 years inclusive.

-Ability to comprehend the investigational nature of the study and provide informed consent. The procedure will be explained to subjects aged 4-17 years with formal consent being obtained from parents or legal guardian.


-Availability of an HLA identical (12/12) matched related or unrelated donor who is available within optimal timeline and suitable considering graft source and established donor selection factors (e.g. age, sex, viral exposure, ABO compatibility, pregnancy status, etc) per PI discretion.

-ECOG performance status of 2 or more.

-Major anticipated illness or organ failure incompatible with survival from transplant.

-Current pregnancy, or unwillingness to take oral contraceptives or use a barrier method of birth control or practice abstinence to refrain from pregnancy, if of childbearing potential for one year.

-HIV positive.

-Diagnosis of Fanconi s anemia (by chromosome breakage study).

-Diffusion capacity of carbon monoxide (DLCO) <40% using DLCO corrected for Hgb or lung volumes (patients under the age of 10 may be excluded from this criterion if they have difficulty performing the test correctly and thus are unable to have their DLCO assessed).

-Left ventricular ejection fraction < 40% (evaluated by ECHO).

-Transaminases > 5x upper limit of normal.

-Serum bilirubin >4 mg/dl.

-Creatinine clearance < 50 cc/min/BSAm2 by 24-hour urine collection adjusted by body surface area.

-Serum creatinine > 2.5 mg/dl

-Presence of an active infection not adequately responding to appropriate therapy.

-History of a malignant disease liable to relapse or progress within 5 years.

-Allergy to bovine, Gentamicin, or to any product which may interfere with the treatment.

-Presence of donor-specific antibodies (DSA) to the umbilical cord blood unit and for cohort 1, to the haplo-identical donor.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Richard W. Childs, M.D.
National Heart, Lung and Blood Institute (NHLBI)
BG 10-CRC RM 3-5330
(301) 451-7128

Jennifer A. Farren
National Heart, Lung and Blood Institute (NHLBI)
National Institutes of Health
Building 10
Room 3-3485
10 Center Drive
Bethesda, Maryland 20892
(301) 594-8013

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--